Week of May 21, 2012: FDA Approves BMS's New Bulk Biologics Manufacturing Facility; SGS Acquires Vitrology; and More - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of May 21, 2012: FDA Approves BMS's New Bulk Biologics Manufacturing Facility; SGS Acquires Vitrology; and More

ePT--the Electronic Newsletter of Pharmaceutical Technology

Bristol-Myers Squibb received FDA approval for its new bulk biologics manufacturing facility in Devens, Massachusetts, for commercial production of Orencia (abatacept). Construction of the Devens facility began in early 2007 and was subsequently completed in 2010. The company submitted the site for regulatory approval in early 2012. Read More

EQT, a Sweden-based private equity group, and Agilent Technologies have agreed to acquire Dako, a Denmark-based diagnostic company, for $2.2 billion. Dako provides antibodies, reagents, scientific instruments and software primarily to pathology laboratories for cancer diagnostics. Dako also collaborates with pharmaceutical companies to develop pharmacodiagnostics or companion diagnostics, which may be used to identify patients most likely to benefit from a specific targeted therapy. The acquisition is expected to close within the next two months and is subject to the satisfaction of customary closing conditions. Read More

SGS has acquired Vitrology, a biopharmaceutical contract testing organization specializing in virology, cell and molecular biology, microbiology, and electron microscopy. The acquisition expands SGS’s Life Science Services global network to 19 laboratories. Read More

Industry Briefs:

A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
22%
To all process for new products only
12%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here